The estimated Net Worth of Matthew Scott Harris is at least $1.02 millió dollars as of 1 February 2024. Dr Harris owns over 13,941 units of Altimmune Inc stock worth over $401,269 and over the last 5 years he sold ALT stock worth over $40,230. In addition, he makes $577,192 as Chief Medical Officer at Altimmune Inc.
Dr has made over 8 trades of the Altimmune Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 13,941 units of ALT stock worth $99,957 on 1 February 2024.
The largest trade he's ever made was exercising 30,000 units of Altimmune Inc stock on 28 February 2022 worth over $57,600. On average, Dr trades about 4,852 units every 65 days since 2019. As of 1 February 2024 he still owns at least 55,965 units of Altimmune Inc stock.
You can see the complete history of Dr Harris stock trades at the bottom of the page.
Dr. Matthew Scott Harris M.D., MS, FCAP, AGAF is the Chief Medical Officer at Altimmune Inc.
As the Chief Medical Officer of Altimmune Inc, the total compensation of Dr AGAF at Altimmune Inc is $577,192. There are 2 executives at Altimmune Inc getting paid more, with Dr. Vipin K. Garg Ph.D. having the highest compensation of $897,696.
Dr AGAF is 68, he's been the Chief Medical Officer of Altimmune Inc since . There are 3 older and 9 younger executives at Altimmune Inc. The oldest executive at Altimmune Inc is David Drutz, 81, who is the Independent Director.
Matthew's mailing address filed with the SEC is C/O ALTIMMUNE, INC., 910 CLOPPER ROAD,, SUITE 201S, GAITHERSBURG, MD, 20878.
Over the last 7 years, insiders at Altimmune Inc have traded over $2,557,810 worth of Altimmune Inc stock and bought 3,362,060 units worth $23,898,779 . The most active insiders traders include Bioventures Ltd Novartis Ag..., Healthcare Capital Partners... és Mitchel Sayare. On average, Altimmune Inc executives and independent directors trade stock every 35 days with the average trade being worth of $432,889. The most recent stock trade was executed by David Drutz on 19 August 2024, trading 41,750 units of ALT stock currently worth $106,463.
altimmune, inc. is a clinical stage biotechnology company developing next-generation immunotherapeutics and vaccines to address significant public health and biodefense needs. by leveraging specific attributes of its two independent and complementary platform technologies, altimmune can rapidly design product candidates against a wide range of disease targets, including respiratory diseases, chronic infections, and cancer. our densigen™ t-cell platform technology is uniquely suited to direct the immune response against traditionally difficult disease targets, including chronic infections and cancer, by directing an individual’s immune system against multiple target antigens instead of just one. altimmune’s respirvec™ platform utilizes convenient needle-free intranasal delivery to achieve broad immunity against disease pathogens more rapidly than conventional vaccines. vaxin’s product candidates are easily manufactured, highly stable, and provide a safe, effective alternative to current
Altimmune Inc executives and other stock owners filed with the SEC include: